Suche
Mein Konto
Llusern is presenting the Lodestar UTI molecular diagnostic platform at Medica 2022
British diagnostics manufacturer Llusern Scientific will preview its Lodestar DX molecular platform at Medica 2022 in Düsseldorf (November 14-17). Llusern will be part of the Welsh Government Pavilion in Hall 16, Stand 38. Photo credit: Llusern Scientific Llusern's first test kit is a panel of tests for urinary tract infections (UTI), including E-coli, Klebsiella and Staphylococcus spp. The UTI assays are expected to receive their UKCA mark in early 2023 and the EU CE mark later this year. Llusern Scientific is a spin-out from the University of South Wales and was founded to develop affordable molecular solutions aimed at treating common infections and diseases...
Llusern is presenting the Lodestar UTI molecular diagnostic platform at Medica 2022
British diagnostics manufacturer Llusern Scientific will preview its Lodestar DX molecular platform at Medica 2022 in Düsseldorf (November 14-17). Llusern will be part of the Welsh Government Pavilion in Hall 16, Stand 38.
Photo credit: Llusern Scientific
Llusern's first test kit is a panel of tests for urinary tract infections (UTI), including E-coli, Klebsiella and Staphylococcus spp. The UTI assays are expected to receive their UKCA mark in early 2023 and the EU CE mark later this year.
Llusern Scientific is a spin-out from the University of South Wales and was founded to develop affordable molecular solutions aimed at detecting common infections and diseases that are currently underserved by existing diagnostics.
Lodestar DX is an easy-to-use testing platform that is portable and delivers highly accurate test results in 40 minutes. The reader aims to bring laboratory-quality molecular diagnostics to point-of-care environments such as doctor's offices, clinics and pharmacists, where Lodestar's simple test preparation and ease of use ensures that minimal user training is required to deliver accurate results.
Dr. Emma Hayhurst, co-founder and CEO of Llusern Scientific, said: "Llusern's aim is to produce cost-effective molecular diagnostic tests that are comparable in accuracy to laboratory-based tests, but are available to everyone when they need them. In doing so, we also want to help combat the over-prescription of antibiotics and respond to global concerns with regard to antimicrobial resistance (AMR).
The current UTI tests available to patients around the world are either outdated and inaccurate or slow and performed in a laboratory. We want to put improving the patient experience at the heart of the diagnostic process and reducing the time it takes to deliver an accurate result is paramount to this.”
Llusern Scientific is a proponent of the “One Health” approach to AMR. In January 2023, the Lodestar UTI Panel will be launched on the veterinary market, where its rapid results and ease of use will make it an invaluable tool to improve antibiotic management, especially for use in dogs and cats where UTIs are common.
.